Ocular Therapeutix said on Tuesday its experimental eye disease drug was more effective in helping patients maintain their vision compared to Regeneron's approved treatment Eylea in a late-stage trial.
CENTRAL TRUST Co cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 56.5% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 519 shares of the biopharmaceutical company's stock after selling 673 shares during the period. CENTRAL TRUST
Assetmark Inc. lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 83.7% in the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 20,819 shares of the biopharmaceutical company's stock after selling 106,802 shares during the quarter. Assetmark Inc.'s holdings in Regeneron Pharmaceuticals were
Advisors Asset Management Inc. reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 23.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,426 shares of the biopharmaceutical company's stock after selling 1,062 shares during the quarter. Advisors
Caprock Group LLC purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) in the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 2,528 shares of the biopharmaceutical company's stock, valued at approximately $1,471,000. Other institutional investors also recently bought and sold shares of
Insight into Mason Hawkins (Trades, Portfolio)' Fourth Quarter 2025 Investment Strategy Mason Hawkins (Trades, Portfolio) recently submitted the 13F filing for
Baird Chautauqua International Growth Fund underperformed its benchmark as stock selection in health care and consumer discretionary detracted most from relative returns. Fanuc reported September quarter results that beat consensus estimates, raising full-year operating profit guidance by 10% on demand recovery and improved utilization rates. Sea Limited reported September quarter results that beat consensus estimates, with revenue growing 38% and gross merchandise value growing 28%.
Regeneron foresees further Eylea decline in 2026 as biosimilars loom, but Eylea HD, Dupixent and Libtayo aim to steady revenues.
TARRYTOWN, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies
Thrivent Financial for Lutherans reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 20.8% in the undefined quarter, according to its most recent filing with the SEC. The firm owned 7,535 shares of the biopharmaceutical company's stock after selling 1,978 shares during the period. Thrivent Financial for Lutherans' holdings in Regeneron Pharmaceuticals
Optimize Financial Inc bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) during the undefined quarter, according to its most recent filing with the SEC. The institutional investor bought 741 shares of the biopharmaceutical company's stock, valued at approximately $417,000. A number of other large investors also recently bought and
Mediolanum International Funds Ltd reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 65.1% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,255 shares of the biopharmaceutical company's stock after selling 2,336 shares during the quarter. Mediolanum International Funds Ltd's holdings
Principal Financial Group Inc. lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 3.9% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 118,483 shares of the biopharmaceutical company's stock after selling 4,766 shares during the
Machina Capital S.A.S. purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 4,615 shares of the biopharmaceutical company's stock, valued at approximately $2,595,000. Several other institutional investors also recently modified
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) on Friday reported upbeat fourth-quarter earnings.
New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated with monthly dosing New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated with monthly dosing
Great Lakes Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,825 shares of the biopharmaceutical company's stock, valued at approximately $1,026,000. Several other institutional
Regeneron is poised for double-digit revenue and EPS growth in 2026, driven by Dupixent and reduced Eylea headwinds. Dupixent's robust expansion and pipeline successors support Regeneron's long-term growth and mitigate post-exclusivity risks. Eylea's decline is moderating, aided by increased patient support and anticipated label expansions.
Total Revenue: $3.9 billion in Q4 2025, up 3% year-over-year.Dupixent Global Net Sales: $4.9 billion in Q4 2025, $17.8 billion for the full year 2025.Libtayo G